IBKS No2 SPAC (KQ:204840) — Market Cap & Net Worth
Market Cap & Net Worth: IBKS No2 SPAC (204840)
IBKS No2 SPAC (KQ:204840) has a market capitalization of $43.12 Million (₩63.63 Billion) as of July 14, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #22436 globally and #1404 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying IBKS No2 SPAC's stock price ₩824.00 by its total outstanding shares 77215186 (77.22 Million). See IBKS No2 SPAC capital reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
IBKS No2 SPAC Market Cap History: 2015 to 2026
IBKS No2 SPAC's market capitalization history from 2015 to 2026. Data shows change from $98.46 Million to $43.12 Million (-7.51% CAGR).
Index Memberships
IBKS No2 SPAC is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$224.31 Billion | 0.02% | #671 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$224.31 Billion | 0.02% | #671 of 1384 |
Weight: IBKS No2 SPAC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
IBKS No2 SPAC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how IBKS No2 SPAC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
IBKS No2 SPAC's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
4.57x
IBKS No2 SPAC's market cap is 4.57 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $204.30 Million | $4.64 Billion | -$5.49 Billion | 0.04x | N/A |
| 2017 | $178.21 Million | $2.41 Billion | -$4.24 Billion | 0.07x | N/A |
| 2018 | $178.46 Million | $8.00 Billion | -$5.35 Billion | 0.02x | N/A |
| 2019 | $57.56 Million | $10.61 Billion | -$5.52 Billion | 0.01x | N/A |
| 2020 | $75.88 Million | $11.99 Billion | -$3.36 Billion | 0.01x | N/A |
| 2021 | $64.89 Million | $12.43 Billion | -$3.73 Billion | 0.01x | N/A |
| 2022 | $39.25 Million | $16.73 Billion | -$790.17 Million | 0.00x | N/A |
| 2023 | $59.44 Million | $26.03 Billion | -$3.75 Billion | 0.00x | N/A |
| 2024 | $51.12 Million | $26.05 Billion | -$2.34 Billion | 0.00x | N/A |
| 2025 | $57.09 Million | $35.27 Billion | $12.49 Million | 0.00x | 4.57x |
Competitor Companies of 204840 by Market Capitalization
Companies near IBKS No2 SPAC in the global market cap rankings as of July 14, 2026.
Key companies related to IBKS No2 SPAC by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #508 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #519 globally with a market cap of $52.04 Billion USD ( CN¥355.63 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #552 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #627 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #508 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #519 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $52.04 Billion | CN¥55.75 |
| #552 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $41.79 |
| #627 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.70 |
IBKS No2 SPAC Historical Marketcap From 2015 to 2026
Between 2015 and today, IBKS No2 SPAC's market cap moved from $98.46 Million to $ 43.12 Million, with a yearly change of -7.51%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩43.12 Million | -24.47% |
| 2025 | ₩57.09 Million | +11.67% |
| 2024 | ₩51.12 Million | -14.00% |
| 2023 | ₩59.44 Million | +51.47% |
| 2022 | ₩39.25 Million | -39.52% |
| 2021 | ₩64.89 Million | -14.48% |
| 2020 | ₩75.88 Million | +31.82% |
| 2019 | ₩57.56 Million | -67.75% |
| 2018 | ₩178.46 Million | +0.14% |
| 2017 | ₩178.21 Million | -12.77% |
| 2016 | ₩204.30 Million | +107.50% |
| 2015 | ₩98.46 Million | -- |
End of Day Market Cap According to Different Sources
On Jul 14th, 2026 the market cap of IBKS No2 SPAC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $43.12 Million USD |
| MoneyControl | $43.12 Million USD |
| MarketWatch | $43.12 Million USD |
| marketcap.company | $43.12 Million USD |
| Reuters | $43.12 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About IBKS No2 SPAC
GL Pharm Tech Corp. provides generic drugs and incrementally modified drug (IMD) formulation technology to pharmaceutical companies in South Korea. The company offers IMD for gastritis, antidepressant, anorectic, and antibiotic indications. It also provides generic drugs for cardiovascular, urology, pain, anti-infection, gastric disease, diabetes, central nervous system disease, respiratory disea… Read more